drugset
drugset / Trial / NCT04371224

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

NCT04371224 ↗

Phase 2 Unknown 200 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.

Timeline

Start
2020-06-23
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — Oral
Comparator Leucovorin Small molecule — Intravenous
Comparator fluorouracil Small molecule — Intravenous
Background Irinotecan Small molecule — —

Indications

malignant pancreatic neoplasm